Previous Close | 2.5600 |
Open | 2.5900 |
Bid | 2.7200 x 200 |
Ask | 2.7700 x 200 |
Day's Range | 2.5500 - 2.8250 |
52 Week Range | 1.3300 - 4.2980 |
Volume | |
Avg. Volume | 444,503 |
Market Cap | 105.015M |
Beta (5Y Monthly) | 2.85 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.0900 |
Earnings Date | May 09, 2024 - May 13, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 7.42 |
Subscribe to Yahoo Finance Plus to view Fair Value for ATHA
Data adds to increasing body of evidence supporting positive modulation of the neurotrophic HGF system as a potential therapeutic approach for neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease, and dementia with Lewy bodies Results from exploratory SHAPE Phase 2 trial show encouraging safety and pro-cognitive measures with fosgonimeton treatment and underscore confidence in Phase 2/3 LIFT-AD trial with data anticipated in the second half of 2024 BOTHELL, Wash., March 08
Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Athira Pharma, Inc. (ATHA) have performed compared to their sector so far this year.
Does Athira Pharma, Inc. (ATHA) have what it takes to be a top stock pick for momentum investors? Let's find out.